JP5941904B2 - 脂質に結合する核酸 - Google Patents

脂質に結合する核酸 Download PDF

Info

Publication number
JP5941904B2
JP5941904B2 JP2013505367A JP2013505367A JP5941904B2 JP 5941904 B2 JP5941904 B2 JP 5941904B2 JP 2013505367 A JP2013505367 A JP 2013505367A JP 2013505367 A JP2013505367 A JP 2013505367A JP 5941904 B2 JP5941904 B2 JP 5941904B2
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
nucleotides
absent
sphingosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013505367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013524792A (ja
JP2013524792A5 (enExample
Inventor
パーシェク，ウェルナー
クラスマン，スヴェン
バフナー，クラウス
シュウォベル，フランク
ホフリグ，カイ
Original Assignee
ノクソン ファーマ エージー
ノクソン ファーマ エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノクソン ファーマ エージー, ノクソン ファーマ エージー filed Critical ノクソン ファーマ エージー
Publication of JP2013524792A publication Critical patent/JP2013524792A/ja
Publication of JP2013524792A5 publication Critical patent/JP2013524792A5/ja
Application granted granted Critical
Publication of JP5941904B2 publication Critical patent/JP5941904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
JP2013505367A 2010-04-21 2011-04-21 脂質に結合する核酸 Expired - Fee Related JP5941904B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10004253 2010-04-21
EP10004253.0 2010-04-21
EP11000117.9 2011-01-10
EP11000117 2011-01-10
PCT/EP2011/002068 WO2011131371A1 (en) 2010-04-21 2011-04-21 Lipid binding nucleic acids

Publications (3)

Publication Number Publication Date
JP2013524792A JP2013524792A (ja) 2013-06-20
JP2013524792A5 JP2013524792A5 (enExample) 2014-06-05
JP5941904B2 true JP5941904B2 (ja) 2016-06-29

Family

ID=44201395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013505367A Expired - Fee Related JP5941904B2 (ja) 2010-04-21 2011-04-21 脂質に結合する核酸

Country Status (5)

Country Link
US (1) US8871920B2 (enExample)
EP (1) EP2561079A1 (enExample)
JP (1) JP5941904B2 (enExample)
CN (1) CN102906265B (enExample)
WO (1) WO2011131371A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140026357A (ko) * 2011-01-10 2014-03-05 녹손 파르마 아게 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법
BR112014016877B1 (pt) 2012-01-10 2022-03-15 Aptarion Biotech Ag Molécula de l-ácido nucleico capaz de se ligar a c5a humana, seus usos, bem como composição farmacêutica, complexo, método para a seleção de um antagonista de uma atividade mediada por c5a e kit para a detecção de c5a
SG11201403769YA (en) 2012-01-10 2014-07-30 Noxxon Pharma Ag Nucleic acids specifically binding cgrp
WO2017143220A1 (en) * 2016-02-17 2017-08-24 Children's Medical Center Corporation Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
EP3264092A1 (en) 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
EP3793427A1 (en) 2018-05-17 2021-03-24 The Procter & Gamble Company Systems and methods for hair coverage analysis
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
EP3814504A1 (en) 2018-06-29 2021-05-05 The Procter & Gamble Company Aptamers for personal care applications
US20200000697A1 (en) * 2018-06-29 2020-01-02 The Procter & Gamble Company Aptamers for hair care applications
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
US11806419B2 (en) 2019-04-16 2023-11-07 The Procter & Gamble Company Aptamers for odor control applications
CA3139314A1 (en) * 2019-07-17 2021-01-21 Noxopharm Limited Immuno-oncology therapy using isoflavone compounds
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6225063B1 (en) * 1998-05-22 2001-05-01 University Technology Corporation RNA channels in biological membranes
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ES2346640T4 (es) 2001-10-26 2011-04-26 Noxxon Pharma Ag Ácido l-nucleico modificado.
EP2138575B8 (en) 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
WO2006052790A2 (en) 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
CA2607185A1 (en) 2005-05-04 2006-11-09 Noxxon Pharma Ag Intracellular active agents
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
EP2407558A1 (en) 2006-10-31 2012-01-18 Noxxon Pharma AG Methods for the detection of a single- or double-stranded nucleic acid molecule

Also Published As

Publication number Publication date
US20130165501A1 (en) 2013-06-27
EP2561079A1 (en) 2013-02-27
AU2011244628A1 (en) 2012-11-08
AU2011244628B2 (en) 2016-01-07
WO2011131371A1 (en) 2011-10-27
AU2011244628A2 (en) 2012-11-08
CN102906265A (zh) 2013-01-30
JP2013524792A (ja) 2013-06-20
CN102906265B (zh) 2016-08-24
US8871920B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
JP5941904B2 (ja) 脂質に結合する核酸
JP6914284B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
CA2565633C (en) Lipids, lipid complexes and use thereof
JP6741673B2 (ja) 抗ｔｎｆ化合物
US8809514B2 (en) Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
JP2020533334A (ja) アポリポタンパク質Ｃ−ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物
CN114901253A (zh) 用于递送核酸的改进的脂质纳米颗粒
JP2024525614A (ja) 筋標的化複合体および筋肉の健康に関連する遺伝子の調整のためのその使用
BRPI0708588A2 (pt) aptámeros de ligaçao ao complemento e agentes anti-c5 usados no tratamento de desordens oculares
KR20120102642A (ko) 축삭 변성의 조절
JP6949916B2 (ja) 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
TWI500425B (zh) 對ｎｇｆ之適體及其用途
JP2025504931A (ja) 関節機能を改善する遺伝子編集
WO2018136831A1 (en) Pseudoknot compositions and methods for inhibiting factor d
TW202146653A (zh) 適體及其用途
WO2018136827A1 (en) Stem-loop compositions and methods for inhibiting factor d
WO2020247850A1 (en) Compositions and methods for inhibiting angiopoietin-2
CN103370414A (zh) 降低恶性神经胶质瘤中下调肾细胞癌的表达的方法
AU2011244628B9 (en) Lipid binding nucleic acids
US20110092575A1 (en) Sirna of human osteopontin
WO2019022986A1 (en) NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR
US20220098591A1 (en) Stem-loop compositions and methods for inhibiting vascular endothelial growtn factor
US20210230599A1 (en) Stem-loop compositions and methods for inhibiting interleukin-8
AU2015268717A1 (en) Lipid binding nucleic acids
CN113383079B (zh) Cxcl8结合性核酸

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160523

R150 Certificate of patent or registration of utility model

Ref document number: 5941904

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees